Combining PIM inhibitors with cisplatin was synergistic in vitro and decreased hepatoblastoma tumor growth in vivo more effectively than either drug alone [100,102], suggesting that PIM inhibition may be employed as a novel therapeutic adjunct to eradicate the SCLCC that may be contributing to drug resistance. This evidence concerns the gene PIM1 and hepatoblastoma.